Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Akouos, Inc. (NASDAQ: AKUS). The acquisition expands Lilly’s efforts in genetic medicines to include Akouos’s portfolio of potential first-in-class adeno-associated viral gene therapies for the treatment of inner ear conditions, including sensorineural hearing loss.
Read the full article: Lilly Completes Acquisition of Akouos Expanding Efforts to Help People with Genetic Diseases //
Source: https://www.prnewswire.com/news-releases/lilly-completes-acquisition-of-akouos-expanding-efforts-to-help-people-with-genetic-diseases-301691496.html